Personalized Approach to Promote Healthy Aging
概览
- 阶段
- 不适用
- 干预措施
- Lifestyle Management
- 疾病 / 适应症
- Aging
- 发起方
- Arizona State University
- 入组人数
- 25
- 试验地点
- 3
- 主要终点
- VO2 max
- 状态
- 进行中（未招募）
- 最后更新
- 4天前
概览
简要总结
The goal of this clinical trial study is to evaluate the impact of a personalized lifestyle intervention on improving healthspan. The primary questions of interest are whether the personalized intervention will result in improvements in muscle function, immune function, and cognitive function in adults aged 50-85 years. Participants will complete baseline assessments, receive an individualized intervention plan for approximately 3 months, and then complete post-intervention assessments. The intervention includes an exercise plan, nutrition recommendations, and general lifestyle goals that will be personalized to each participant.
研究者
Susan Racette
Professor
Arizona State University
入排标准
入选标准
- •50-85 years of age
- •Non-smoking
- •Ambulatory without the need of an assistive device (walker, cane, etc.) and able to perform exercise testing and exercise training
- •English speaking
- •Owns a smart phone
排除标准
- •Minors and adults younger than age 50 years and older than 85 years
- •Pregnant women
- •Adults who are unable to provide informed consent
- •Prisoners
研究组 & 干预措施
Lifestyle Intervention
All participants will receive an intervention.
干预措施: Lifestyle Management
结局指标
主要结局
VO2 max
时间窗: From baseline to the end of the intervention at 3 months.
A maximal treadmill exercise test with respiratory gas exchange analysis to assess cardiorespiratory fitness.
Biodex
时间窗: From baseline to the end of the intervention at 3 months.
A Biodex will be used to assess leg muscle power and strength.
次要结局
- World Health Organization Quality of Life Survey(From baseline to the end of the intervention at 3 months.)
- Pittsburgh Sleep Quality Index(From baseline to the end of the intervention at 3 months.)
- Handgrip strength(From baseline to the end of the intervention at 3 months.)
- Dual Energy X-ray Absorptiometry (DXA)(From baseline to the end of the intervention at 3 months.)
- Waist circumference(From baseline to the end of the intervention at 3 months.)
- Hip circumference(From baseline to the end of the intervention at 3 months.)
- Systolic blood pressure(From baseline to the end of the intervention at 3 months.)
- Diastolic blood pressure(From baseline to the end of the intervention at 3 months.)
- Digit Symbol Substitution Test (DSST)(From baseline to the end of the intervention at 3 months.)
- Montreal Cognitive Assessment (MoCA)(From baseline to the end of the intervention at 3 months.)
- Short Physical Performance Battery(From baseline to the end of the intervention at 3 months.)
- Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Hemoglobin A1C Concentration(From baseline to the end of the intervention at 3 months.)
- Insulin Concentration(From baseline to the end of the intervention at 3 months.)
- Geriatric Depression Scale (GDS)(From baseline to the end of the intervention at 3 months.)
- Generalized Anxiety Disorder (GAD)-7(From baseline to the end of the intervention at 3 months.)
- Perceived Stress Scale(From baseline to the end of the intervention at 3 months.)
- High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Brief Resilience Scale(From baseline to the end of the intervention at 3 months.)
- Non-High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Very Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- CD3 T cells(From baseline to the end of the intervention at 3 months.)
- CD4 T cells(From baseline to the end of the intervention at 3 months.)
- CD8 T cells(From baseline to the end of the intervention at 3 months.)
- Natural Killer cells(From baseline to the end of the intervention at 3 months.)
- B cells(From baseline to the end of the intervention at 3 months.)